Pharma industry’s deal value decreases by 76.8 per cent in April 2022

The industry reported 113 Venture Capital (VC) deals worth $2.6 billion in April 2022, compared to the last 12-month average (April 2021 to March 2022) of 168 deals worth $4.7 billion

The latest report by GlobalData has revealed that the pharma industry reported 77 deals worth $7.2 billion as compared to the last 12-month average (April 2021 to March 2022) of 84 deals worth $16.6 billion.

GlaxoSmithKline (GSK) to acquire Sierra Oncology for $55 per share of common stock in cash, representing an approximate total equity value of $1.9 billion; Halozyme Therapeutics to acquire Antares Pharma for approximately $960 million; and Global Cord Blood Corporation to acquire Cellenkos for $801.5 million, were the three major deals which contributed 49 per cent of the total deal value during April 2022, the report notified.

It also mentioned that the industry reported 113 Venture Capital (VC) deals worth $2.6 billion in April 2022, compared to the last 12-month average (April 2021 to March 2022) of 168 deals worth $4.7 billion.

Tessera Therapeutics raising over $300 million in Series C financing to advance its gene writing platform; Be Biopharma raising $130 million in series B financing to advance autologous and allogeneic Engineered B Cell Medicine (BeCM) platforms, as well as progress pipeline candidates in oncology and rare disease towards Investigational New Drug (IND) applications; and Sionna Therapeutics raising $111 million Series B financing to advance pipeline of novel small molecules with the potential to fully restore CFTR function in cystic fibrosis, were the major VC deals reported in April 2022, the statement concluded.

GlobalData Reportpharma dealspharma industry
Comments (0)
Add Comment